Evidence map›Paper›PMID 19650904›Full record

ArticleBMC immunology2009

Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.

Claudius Grossmann, Matthias Tenbusch, Godwin Nchinda, Vladimir Temchura, Ghulam Nabi, Geoffrey W Stone, Richard S Kornbluth, Klaus Uberla

Open access · goldAbstract read
In one paragraph

Article in BMC immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Adaptation in the innate immune system and heterologous innate immunity.Cellular and molecular life sciences : CMLS · 2014
    Review
  8. Article
  9. Gold nanoparticle mediated cancer immunotherapy.Nanomedicine : nanotechnology, biology, and medicine · 2014
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Claudius GrossmannDepartment of Molecular and Medical Virology, Ruhr-Universität Bochum, Universitätsstrasse 150, 44801 Bochum, Germany. claudius.grossmann@rub.de
Matthias Tenbusch
Godwin Nchinda
Vladimir Temchura
Ghulam Nabi
Geoffrey W Stone
Richard S Kornbluth
Klaus Uberla
Ruhr University Bochum · DERockefeller University · USUniversity Hospitals of the Ruhr-University of Bochum · DEUniversity of California, San Diego · USUniversity of Miami · US

Funding

Immunostimulatory single cycle SIV Vaccines incorporating TRAF-mediated molecularR21AI078834 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI STONE, GEOFFREY WILLIAM · 2008 to 2009
$598k
Vaccines to Generate Neutralizing Anti-HIV AntibodiesR21AI073240 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI KORNBLUTH, RICHARD SYD · 2007 to 2008
$379k
CD40L and GITRL adjuvants for adenoviral vaccines against HIVK22AI068489 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI STONE, GEOFFREY WILLIAM · 2008 to 2009
$270k
NIAID NIH HHS K22 AI068489NIAID NIH HHS K22AI068489NIAID NIH HHS R21 AI073240NIAID NIH HHS R21AI073240NIAID NIH HHS R21 AI078834NIAID NIH HHS R21AI078834
6 · The paper itself

Abstract

backgroundTargeting of protein antigens to dendritic cells (DC) via the DEC205 receptor enhances presentation of antigen-derived peptides on MHC-I and MHC-II molecules and, in the presence of costimulatory signals, antigen-specific immune responses. The immunogenicity and efficacy of DNA vaccination can also be enhanced by fusing the encoded antigen to single chain antibodies directed against DEC205. To further improve this strategy, we evaluated different toll-like receptor ligands (TLR) and CD40 ligands (CD40L) as adjuvants for DNA vaccines encoding a DEC205-single-chain antibody fused to the ovalbumin model antigen or HIV-1 Gag and assessed the priming efficacy of DNA in a DNA prime adenoviral vector boost immunization regimen.

resultsMice were primed with the adjuvanted DEC-205 targeted DNA vaccines and boosted with adenoviral vectors encoding the same antigens. CD8+ T cell responses were determined after the adenoviral booster immunization, to determine how well the different DNA immunization regimens prime for the adenoviral boost. In the absence of adjuvants, targeting of DNA-encoded ovalbumin to DCs suppressed CD8+ T-cell responses after the adenoviral booster immunization. CD8+ T-cell responses to the DEC205 targeted DNA vaccines increased only slightly by adding either the TLR-9 ligand CpG, the TLR-3 ligand Poly I:C, or CD40 ligand expression plasmids. However, the combination of both TLR-ligands led to a strong enhancement of CD8+ T-cell responses compared to a non-targeted DNA vaccine. This finding was confirmed using HIV Gag as antigen.

conclusionAlthough DNA prime adenoviral vector boost immunizations belong to the strongest inducers of cytotoxic T cell responses in different animal models and humans, the CD8+ T cell responses can be further improved by targeting the DNA encoded antigen to DEC205 in the presence of synergistic TLR ligands CpG and Poly I:C.

Indexed as

Antigen PresentationAdjuvants, ImmunologicAnimalsAntigens, CDCD40 LigandCD8-Positive T-LymphocytesDendritic CellsFemaleGene Products, gagGenetic VectorsHIVLectins, C-TypeLigandsMiceMice, Inbred BALB CMice, Inbred C57BLAdjuvants, ImmunologicAntigens, CDCD40 LigandCPG-oligonucleotideDEC-205 receptorGene Products, gagLectins, C-TypeLigandsMinor Histocompatibility AntigensOligodeoxyribonucleotidesOvalbuminPoly I-CReceptors, Cell SurfaceRecombinant Fusion ProteinsToll-Like ReceptorsVaccines, DNA

Identifiers

PMID19650904
PMCPMC2731061
OpenAlexW2125430546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.